Welcome to Shelys Pharmaceuticals, a renowned pharmaceutical company of Sub Saharan Africa. Shelys has humble origins starting as a diminutive family business in 1956 and has, over the years, established itself to be one of the largest pharmaceutical companies in East Africa.
Shelys has its footprints in Tanzania ,Zambia ,Malawi ,DRC, Rwanda , Burundi, Mozambique, Madagascar ,Mauritius, Djibouti ,Uganda and Kenya and is a leader in the script market for crucial therapeutic categories such as cough and cold, anti infectives, nutraceuticals, antimalarials, gastro intestinal, pain management, fever and topical inflammation, disinfectants, cardiovascular and erectile dysfunction.
In 2012, Aspen Pharmacare Holdings Limited (Aspen) acquired the remaining share in Shelys Pharmaceuticals Limited providing for a 100% shareholding.Tanzania-based Shelys and Beta Healthcare based in Kenya, a prominent leader in OTC business in Sub Saharan Africa, are both subsidiaries of Shelys Africa. This alliance provides the foundation of Aspen’s expansion into the East and Central African market and the establishment of an affordable, quality, generics brand presence on the continent.
The African continent offers a promising window of opportunity for pharmaceutical expansion. South African-based Aspen Pharmacare, which has manufacturing facilities valued in excess of R1 billion and which produce approximately 6 billion tablets per annum, is suitably positioned to manufacture and supply product across Africa.
With its South African presence established, Aspen has been actively engaged in securing strategic alliances with international partners, including those based in Africa, in a bid to increase its geographic footprint in this territory.
Aspen’s position in Africa through its relationships with international pharmaceutical companies Gilead Sciences Inc and Tibotec Pharmaceuticals Limited, has positioned the company at the forefront of introducing first world technology to the continent to support the implementation of the latest guidelines and protocols for the treatment of HIV/Aids.
Aspen’s range of anti-retrovirals, which include treatment products such as Viread, Truvada and Presista, has established the Group as a valued contributor in the fight against HIV/Aids on the continent.
Aspen’s strategic approach toward providing meaningful solutions against infectious diseases, as well as securing appropriate international partnerships, has created an opportunity for the Group to create a pharmaceutical legacy across the African continent.
Sanjay Advani, Director & CEO - SSA (Aspen) Briefing to Aspen personnels in Sub Saharan Africa...Read more...
..... Get more on Forbes Africa -'PENRESA FOCUS ON TANZANIA' EditionRead more...
Shelys Pharmaceuticals Limited winner of the top Pharmaceutical Manufacturer Award, in the sector...Read more...
Kama Ltd emerged the winner in this year’s HELEH AFRICA , bagging the prestigious title Africa...Read more...
Eco-balance is a key issue in the current discussions and in saving our planet.
Depletion of fossil fuels CO2 emissions and global warming are a threat to our ecologic and economic balance.
Our company aims to contribute to ensuring eco-balance by taking initiatives towards energy saving and low carbon emissions.
Environmental management protocols are being developed in accordance with ISO 14001 to enable the company to participate in Carbon Disclosure Project (CDP) in a near future.
Shelys takes water as a resource which is limited and therefore continually puts in measures to conserve water. It comes up with Environmental Management Programmes with set targets as part of its annual objectives in Water Conservation.
Process waste water is treated to ensure set parameters are met before the water is discharged into the public sewer as per the requirements of EMCA Water Regulations of 2006. The company has in place a waste water treatment facility with enough capacity to treat the waste water to the required quality as required under the Water Quality Regulations.
Shelys has in place an energy policy. Energy audits have been carried out and energy conservation programmes initiated as per requirements under Energy Act. The energy conservation programmes are taken as part of annual Environmental management programmes and objectives are set with targets to be achieved in energy use. Continuous monitoring of the programmes is done to ensure achievement of the set objectives and targets.
Air quality measurements are done on an annual basis to ensure that what is emitted is within required regulatory requirements. Exhaust emissions from the boiler, generator and industrial trucks are measured to ensure that emissions levels are within specified regulatory limits as provided under EMCA-Air Quality Regulations, 2015. Measurements are done for particulate and VOCs in the work stations to ensure personnel are working in a conducive environment as per the requirements under Occupational Health and Safety Act-Hazardous Substance Rules and WHO guidelines.
Structured waste management processes are implemented. Continual improvement initiatives are undertaken on the waste handling procedures.
As per the Cap 244, the Pharmacy and Poisons Act, Laws of Tanzani, all pharmaceutical wastes must be handled responsibly owing to the security risk around pharmaceutical products. The pharmaceutical waste and other hazardous wastes are handled in accordance with the Environment Management and Coordination Act (EMCA), Waste Regulations of 2006.
The wastes are segregated, recorded, properly stored before they are disposed off. All wastes are disposed off using NEMA approved waste handlers for transportation and disposal sites. Waste recycling and reuse opportunities have been implemented for non-hazardous waste.
The central waste yard at Shelys has been designed for more efficient handling and compliance to the Waste Management Regulations and to the Aspen standards for waste management.
Shelys has under taken a comprehensive Hazard Identification and Risk Assessment and kept in place mitigation measures for the identified risks. This has been done to proactively prevent incidents at the workplace. All incidents are investigated and corrective actions proposed and implemented to prevent reoccurrence. Key performance indicators are in place to measure SHE performance in terms of accident rates. The company aims at having minimum cases of accidents in line with its SHE policy.
Shelys takes compliance to regulatory requirements as key to its operations. It has a legal register which is updated quarterly and a legal unit which aids in updating the company on legal issues. Legal audits are done annually to check the level of compliance and propose corrective measures for any noncompliance noted.
As part of its business continuity strategy, Shelys has identified the emergency situations it anticipates and kept in place emergency response plans. It has procedures for response to the emergencies and also tests these procedures periodically to ensure adequate preparedness. All employees are trained on steps to take during emergency situations.